Browse our 1,000+ Publications​

Latest Publications

Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial

Izutsu K, et al.
Leukemia Lymphoma
July 2025
Authors and Affiliates
Koji Izutsua, Daigo Akahaneb, Tomomi Toubaic, Toko Saitod, Yuko Mishimae, Tomoaki Fujisakif, Momoko Nishikorig, Takahiro Kumodeh, Youko Suehiroi, Kenji Ishitsukaj, Rebekah Conlonk, Ami Takahashil, Barbara D’Angelo Månssonm, Elena Favarom and Noriko Fukuharan aDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan; bDepartment of Hematology, Tokyo Medical University, Tokyo, Japan; cDepartment of Internal Medicine III, Division of Hematology and Cell Therapy, Yamagata University Faculty of Medicine, Yamagata, Japan; dDepartment of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan; eDepartment of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; fDepartment of Hematology, Japan Red Cross Society, Matsuyama Red Cross Hospital, Matsuyama, Japan; gDepartment of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; hDepartment of Hematology and Rheumatology, Kindai University, Osaka, Japan; iDepartment of Hematology and Cell Therapy, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; jDepartment of Hematology and Rheumatology, Kagoshima University, Kagoshima, Japan; kAbbVie, North Chicago, IL, USA; lGenmab, Tokyo, Japan; mGenmab, Copenhagen, Denmark; nDepartment of Hematology, Tohoku University, Sendai, Japan

Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study

Kumar S, et al.
Lancet Haematology
June 2025
Authors and Affiliates
Shaji K Kumar, Simon J Harrison, Michele Cavo, Javier de la Rubia, Rakesh Popat, Cristina Gasparetto, Vania Hungria, Hans Salwender, Kenshi Suzuki, Inho Kim, Maika Onishi, Grace Ku, Rajvineeth Pothacamury, Muhammad Jalaluddin, Jiewei Zeng, Jeremy A Ross, Edyta Dobkowska, Philippe Moreau Mayo Clinic, Rochester, MN, USA (Prof S K Kumar MD); Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia (Prof S J Harrison PhD); Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia (Prof S J Harrison); IRCCS Azienda Ospedaliero- Universitaria di Bologna, Seragnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy (Prof M Cavo MD); Hematology Service Hospital La Fe, IIS La Fe, and School of Medicine and Dentistry, Catholic University of Valencia, Valencia, Spain (Prof J de la Rubia MD); University College London Hospitals NHS Foundation Trust, London, UK (R Popat FRCPath); Duke University Medical Center, Durham, NC, USA (Prof C Gasparetto MD); Clinica São Germano, São Paulo, Brazil (Prof V Hungria MD); Asklepios Tumorzentrum Hamburg, AK Altona and AK St Georg, Hamburg, Germany (H Salwender MD); Japanese Red Cross Medical Center, Tokyo, Japan (Prof K Suzuki MD); Seoul National University, Seoul, South Korea (Prof I Kim MD); Genentech, Inc, South San Francisco, CA, USA (M Onishi MD, G Ku MD); AbbVie, North Chicago, IL, USA (R Pothacamury MD, M Jalaluddin PhD, J Zeng PhD, J A Ross PhD); AbbVie, Schaffhausen, Switzerland (E Dobkowska MD); University Hospital Hôtel-Dieu, Nantes, France (Prof P Moreau MD)

Indirect Comparison of Linvoseltamab Versus Teclistamab for the Treatment of Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

Lee H, et al.
Clin Lymphoma Myeloma Leuk
June 2025
Authors and Affiliates
Hans C. Lee,1 Naresh Bumma,2 Joshua Richter,3 Jeffrey A. Zonder,4James E. Hoffman,5 Zheng-Yi Zhou,6 Viviana García-Horton,6 Mirko Fillbrunn,6Hongjue Wang,6 Matthew Mattera,6 Wenxin Ma,6 Timothy J. Inocencio,7Yingxin Xu,7 Evelien Bergrath,7 James Harnett,7 Tito Roccia,7 Kate Knorr,7Glenn S. Kroog,7 Karen Rodriguez Lorenc,7 Qiufei Ma,7 Sundar Jagannath3 1 Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX2 Division of Hematology/Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH3 Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY4 Department of Hematology and Oncology, Karmanos Cancer Institute, Detroit, MI5 Department of Medicine, Division of Hematology/Oncology, University of Miami Health System, Miami, FL6 Analysis Group, Inc., Boston, MA7 Department of Oncology, Regeneron Pharmaceuticals, Inc., Tarrytown, NY

T and B cell responses against Epstein–Barr virus in primary sclerosing cholangitis

Hesham ElAbd, et al.
Nature Medicine
June 2025
Authors and Affiliates
Hesham ElAbd, Mitchell Pesesky, Gabriel Innocenti, Brian K. Chung, Aya K. H. Mahdy, Valeriia Kriukova, Laila Kulsvehagen, Dennis Strobbe, Claudia Stühler, Gabriele Mayr, Damon H. May, Melanie Prinzensteiner, Tim A. Steiert, Florian Tran, Michel V. Hadjihannas, Rainer Günther, Elisa Rosati, Sören Mucha, Wolfgang Lieb, Malte Ziemann, Astrid Dempfle, Felix Braun, Trine Folseraas, Johannes R. Hov, Espen Melum, Petra Bacher, Martina Sterneck, Tobias J. Weismüller, Henrike Lenzen, Bernd Bokemeyer, Bryan Howie, Harlan S. Robins, Christoph Röcken, Stefan Schreiber, Nina Khanna, Anne-Katrin Pröbstel, Christoph Schramm, Thomas Vogl, Tom H. Karlsen & Andre Franke

Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma

Perrot A, et al.
June 2025
Authors and Affiliates
Aurore Perrot, M.D.,1 Jérôme Lambert, Ph.D.,2 Cyrille Hulin, M.D.,3 Andrea Pieragostini, M.D.,4 Lionel Karlin, M.D.,5 Bertrand Arnulf, M.D.,6 Philippe Rey, M.D.,7 Laurent Garderet, M.D.,8 Margaret Macro, M.D.,9 Martine Escoffre‑Barbe, M.D.,10 Julie Gay, M.D.,11 Thomas Chalopin, M.D.,12 Romain Gounot, M.D.,13 Jean‑Marc Schiano, M.D.,14 Mohamad Mohty, M.D.,15 Xavier Leleu, M.D.,16 Salomon Manier, M.D.,17 Clara Mariette, M.D.,18 Carine Chaleteix, M.D.,19 Thorsten Braun, M.D.,20 Bernard De Prijck, M.D.,21 Hervé Avet‑Loiseau, M.D.,22 Jean‑Yves Mary, Ph.D.,2 Jill Corre, Pharm.D.,22 Philippe Moreau, M.D.,23 and Cyrille Touzeau, M.D.23 1 Service Hématologie, Hôpital Universitaire de Toulouse Oncopole, Université de Toulouse, Toulouse, France; 2 Biostatistics and Medical Information Department, Hôpital St. Louis, Paris; 3 Service d’Hématologie, Hôpital Haut Lévêque, Centre Hospitalier Universitaire (CHU) de Bordeaux, Pessac, France; 4 Service Hématologie, Hôpital Universitaire de Dijon, Dijon, France; 5 Service Hématologie, Hôpital Universitaire Lyon Sud, Pierre-Bénite, France; 6 Hôpital Universitaire St. Louis, Assistance Publique–Hôpitaux de Paris (AP-HP), Paris; 7 Centre Léon Bérard, Lyon, France; 8 Service Hématologie, Hôpital Universitaire Pitié-Salpêtrière, AP-HP, Paris; 9 Service Hématologie, Institut Hématologie de Basse Normandie, Hôpital Universitaire de Caen, Caen, France; 10 Service Hématologie, Hôpital Universitaire de Rennes, Rennes, France; 11 Hôpital de Bayonne, Bayonne, France; 12 Service Hématologie, Hôpital Universitaire de Tours, Tours, France; 13 Service Hématologie, Hôpital Henri Mondor, Créteil, France; 14 Service Hématologie, Institut Paoli- Calmettes, Marseille, France; 15 Service Hématologie, Hôpital Universitaire St. Antoine, AP-HP, Université Sorbonne, Paris; 16 Service Hématologie, Hôpital Universitaire de Poitiers, Poitiers, France; 17 Service Hématologie, Hôpital Universitaire de Lille, Lille, France; 18 Service Hématologie, Hôpital CHU de Grenoble, Grenoble, France; 19 Service Hématologie, Hôpital Universitaire de Clermont-Ferrand, Clermont-Ferrand, France; 20 Service Hématologie, Hôpital Avicenne, AP-HP, Paris; 21 Service Hématologie, Hôpital Universitaire de Liège, Liège, Belgium; 22 Unité Génomique du Myélome, Hôpital Universitaire de Toulouse Oncopole, Université de Toulouse, Toulouse, France; 23 Service Hématologie, Hôpital Universitaire

Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma

Kubicki T, et al.
Blood Neoplasia
June 2025
Authors and Affiliates
Tadeusz Kubicki,1,2 Benjamin A Derman,1 Jennifer H Cooperrider,1 Anna Puła,1,3 David Barnidge,4 Dominik Dytfeld,2 Ken Jiang,1 Andrzej J Jakubowiak1 1University of Chicago, Chicago, Illinois, USA; 2Poznan University of Medical Sciences, Poznan, Poland; 3 Medical University of Lodz, Lodz, Poland 4Binding Site, part of Thermo Fisher, Rochester, NY, USA

Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma

Jagannath S, et al
J Clin Oncol
June 2025
Authors and Affiliates
Sundar Jagannath, MD, FASCO1 ; Thomas G. Martin, MD2; Yi Lin, MD, PhD3 ; Adam D. Cohen, MD4 ; Noopur Raje, MD5 ; Myo Htut, MD6; Abhinav Deol, MD7 ; Mounzer Agha, MD8 ; Jesus G. Berdeja, MD9 ; Alexander M. Lesokhin, MD10; Jessica J. Liegel, MD11 ; Adriana Rossi, MD1 ; Alex Lieberman-Cribbin, MPH, CCRP1 ; Saad Z. Usmani, MD, MBA, FACP, FASCO10 ; Binod Dhakal, MD12 ; Samir Parekh, MD1 ; Hui Li, PhD13; Feng Wang, PhD13; Rocio Montes de Oca, PhD14 ; Vicki Plaks, PhD, LLB14; Huabin Sun, MD15; Arnob Banerjee, MD, PhD14; Jordan M. Schecter, MD15; Nikoletta Lendvai, MD, PhD15; Deepu Madduri, MD15; Tamar Lengil, PhD15; Jieqing Zhu, PhD16; Mythili Koneru, MD, PhD16; Muhammad Akram, MD16; Nitin Patel, BM BCh16; Octavio Costa Filho, MD16; Andrzej J. Jakubowiak, MD, PhD17 ; and Peter M. Voorhees, MD18 1Icahn School of Medicine at Mount Sinai, New York, NY 2University of California, San Francisco, San Francisco, CA 3Mayo Clinic, Rochester, MN 4Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 5Massachusetts General Hospital Cancer Center, Boston, MA 6Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA 7Karmanos Cancer Institute, Wayne State University, Detroit, MI 8UPMC Hillman Cancer Center, Pittsburgh, PA 9Tennessee Oncology, Nashville, TN 10Memorial Sloan Kettering Cancer Center, New York, NY 11Division of Hematologic Malignancies and Bone Marrow Transplantation, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 12Medical College of Wisconsin, Milwaukee, WI 13Johnson & Johnson, Shanghai, China 14Johnson & Johnson, Spring House, PA 15Johnson & Johnson, Raritan, NJ 16Legend Biotech USA Inc, Somerset, NJ 17University of Chicago, Chicago, IL 18Atrium Health/Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC

Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab

J hematol oncol
May 2025
Authors and Affiliates
Nicholas J. Short1, Hagop Kantarjian1, Ken Furudate1, Nitin Jain1, Farhad Ravandi1, Omer Karrar1, Sanam Loghavi2, Lewis Nasr1, Fadi G. Haddad1, Jayastu Senapati1, Rebecca Garris1, Koichi Takahashi1 and Elias Jabbour1 1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1515 Holcombe Boulevard, Houston, TX 77030, USA 2Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Real world performance of the CALGB 10403 regimen in young adults in the United States

DaSilva B, et al.
Blood Neoplasia
May 2025
Authors and Affiliates
Brandon DaSilva1,2, Alicia Darwin1, Amy Zhang3, Rutu D. Vyas4, Kathryn Russell5, Jason S. Gilbert6, Virginia Tan7, Susan Feldt8, Hannah Johnston9, Emily C Liang4,10, Adam S. DuVall9, Michaela Liedtke11, Wendy Stock9, Ryan D. Cassaday4,5, Marc Schwartz12, Jessica T. Leonard13, Lori S. Muffly14*, Marlise R. Luskin15 1Department of Medicine, Stanford University School of Medicine, Stanford, CA 2Division of Hematology Oncology, Department of Medicine, Columbia University, New York, NY 3Stanford University School of Medicine, Stanford, CA 4Clinical Research Division Fred Hutchinson Cancer Center, Seattle, WA 5University of Washington School of Medicine, Seattle, WA 6Department of Medicine, University of Colorado School of Medicine, Aurora, CO 7Department of Medicine, Oregon Health & Science University, Portland, OR 8Department of Medicine, University of Chicago, Chicago, IL 9Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL 10Department of Medicine, University of Washington, Seattle, WA 11Stanford Cancer Center, Palo Alto, CA 12Division of Hematology, University of Colorado, Aurora, CO 13Department of Hematology & Medical Oncology, Oregon Health and Science University, Portland, OR 14Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA 15Division of Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

Blood-based Measurable Residual Disease by Clonotypic Mass Spectrometry is Prognostic in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant

Slade M, et al.
Clin Lymphoma Myeloma Leuk
May 2025
Authors and Affiliates
Michael J. Slade, MD, MSCI1*, Julie Fortier, PhD1, Abir Khaled, PhD2, Mark Fiala, PhD1, Zac McDonald, PhD2, Mark A. Zaydman, MD, PhD3, Fei Wan, PhD4, Mark A. Schroeder, MD1, Keith Stockerl-Goldstein, MD1, Liqiang Yang, PhD2, Ravi Vij, MD, MBA1 *Corresponding author 1Division of Oncology, Department of Medicine, Washington University in Saint Louis, St. Louis, MO, USA 2Rapid Novor, Kitchener, Ontario, Canada 3Division of Laboratory and Genomic Medicine, Department of Pathology, Washington University in Saint Louis, St. Louis, MO, USA 4Division of Public Health Sciences, Washington University in Saint Louis, St. Louis, MO, USA
Previous Next